slides · global inventory
Comparison Frame
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,294
Current window 4,741-4,770
Pages 210
Rows per page 30
Framework
4,741-4,770 of 6,294
08
The slide uses a comparison frame to contrast small molecule data availability with biologic data scarcity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
34
The chart uses a grouped bar format to compare five economic categories: Research Funding/Cost, Upfront Payment, Clinical Milestones, Commercial Milestones, and Royalties.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
100
The slide uses a side-by-side comparison structure to detail the value proposition of two specific drug candidates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
10
The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Competition1 hit
29
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
30
The chart uses a stacked bar to visualize the additive nature of the combination therapy compared to the individual components.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
31
The table highlights that Spyre's products possess specific safety and efficacy features (no black box warning, dual mechanism, extended half-life) that the competitor lacks.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
21
The table uses checkmarks to indicate the presence of specific therapeutic benefits across different drug classes.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Uses a comparative structure to show breadth of service.Azerion | Investor Presentation Deck | 34 slides · Azerion
Pitch deck Investor relations Beat · Traction1 hit
49
The slide uses a color-coded heatmap to visualize performance against a Target Product Profile (TPP).Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
32
The chart shows a 108 bps delta between the peer group and the company's adjusted metric.First Foundation | Investor Presentation Deck | 47 slides · First Foundation
Pitch deck Investor relations Beat · Financials1 hit
18
The chart shows a clear performance gap between FFIC and the industry average.Flushing Financial | Investor Presentation Deck | 32 slides · Flushing Financial
Conference presentation Investor relations Beat · FinancialsLoop · Benchmark Gap1 hit
17
The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
The slide uses three side-by-side bar charts to demonstrate dominance in specific financial advisory niches.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
10
The slide uses a series of bar charts to demonstrate market leadership across multiple verticals.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
17
Includes detailed clinical trial references in the footer.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a bar chart to compare TCO (Total Cost of Ownership) between VinFast models and specific Tesla/Hyundai models.VinFast | Investor Presentation Deck | 33 slides · VinFast
Pitch deck Investor relations 1 hit